Abstract
Hepatitis C virus (HCV), the major etiological agent of transfusion-associated non-A, non-B hepatitis, is a severe health problem affecting up to 3% of the world population. Since its identification in 1989, enormous efforts have been made to characterize the viral cycle. However, many details regarding the virus penetration of hepatocytes, its replication and translation, and the assembling of virions remain unknown, mostly because of a lack of an efficient culture system. This has also hampered the development of fully effective antiviral drugs. Current treatments based on the combination of interferon and ribavirin trigger a sustained virological response in only 40% of infected individuals, thus the development of alternative therapeutic strategies is a major research goal. Nucleic acid based therapeutic agents may be of some potential in hepatitis C treatment. In recent years, much effort has gone into the improvement of DNA and RNA molecules as specific gene silencing tools. This review summarizes the state of the art in the development of new HCV therapies, paying special attention to those involving antisense oligonucleotides, aptamers, ribozymes, decoys and siRNA inhibitors. The identification of potential viral targets is also discussed.
Keywords: HCV, hepatitis C, gene silencing, RNA-based inhibitors, ribozyme, antisense, aptamer, siRNA
Infectious Disorders - Drug Targets
Title: Targets and Tools: Recent Advances in the Development of Anti-HCV Nucleic Acids
Volume: 6 Issue: 2
Author(s): C. Romero-Lopez, F. J. Sanchez-Luque and A. Berzal-Herranz
Affiliation:
Keywords: HCV, hepatitis C, gene silencing, RNA-based inhibitors, ribozyme, antisense, aptamer, siRNA
Abstract: Hepatitis C virus (HCV), the major etiological agent of transfusion-associated non-A, non-B hepatitis, is a severe health problem affecting up to 3% of the world population. Since its identification in 1989, enormous efforts have been made to characterize the viral cycle. However, many details regarding the virus penetration of hepatocytes, its replication and translation, and the assembling of virions remain unknown, mostly because of a lack of an efficient culture system. This has also hampered the development of fully effective antiviral drugs. Current treatments based on the combination of interferon and ribavirin trigger a sustained virological response in only 40% of infected individuals, thus the development of alternative therapeutic strategies is a major research goal. Nucleic acid based therapeutic agents may be of some potential in hepatitis C treatment. In recent years, much effort has gone into the improvement of DNA and RNA molecules as specific gene silencing tools. This review summarizes the state of the art in the development of new HCV therapies, paying special attention to those involving antisense oligonucleotides, aptamers, ribozymes, decoys and siRNA inhibitors. The identification of potential viral targets is also discussed.
Export Options
About this article
Cite this article as:
Romero-Lopez C., Sanchez-Luque J. F. and Berzal-Herranz A., Targets and Tools: Recent Advances in the Development of Anti-HCV Nucleic Acids, Infectious Disorders - Drug Targets 2006; 6 (2) . https://dx.doi.org/10.2174/187152606784112182
DOI https://dx.doi.org/10.2174/187152606784112182 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Matrix Metalloproteinases as Drug Targets in Acute Pulmonary Embolism
Current Drug Targets The Possible Adverse Effects of Intramuscular Botulinum Toxin Injections and their Management
Current Drug Safety Design of Multifunctional Compounds for Cardiovascular Disease: From Natural Scaffolds to “Classical” Multitarget Approach
Current Medicinal Chemistry Isoniazid: Metabolic Aspects and Toxicological Correlates
Current Drug Metabolism Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Toll-Like Receptors and Inflammation in the CNS
Current Drug Targets - Inflammation & Allergy Fetal Undernutrition and the Programming of Blood Pressure
Current Nutrition & Food Science Genetically Engineered Elastin-based Biomaterials for Biomedical Applications
Current Medicinal Chemistry Effects of Antiplatelet Medication on Arteriovenous Fistula Patency After Surgical Thrombectomy
Current Vascular Pharmacology The Use of Antiparkinsonian Agents in the Management of Drug-Induced Extrapyramidal Symptoms
Current Pharmaceutical Design Lactic Acidosis, Hypotension, and Sensorineural Hearing Loss Following Intentional Metformin Overdose
Current Drug Safety A Review of Voltammetric Methods for Determination of Dopamine Agonists
Current Analytical Chemistry Which Drugs for the Control of Fever in Critical Patients
Current Drug Targets Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus
Current Drug Safety Chemical Intuition in Drug Design and Discovery
Current Topics in Medicinal Chemistry The Urokinase Receptor System, A Key Regulator at the Intersection between Inflammation, Immunity, and Coagulation
Current Pharmaceutical Design Why Methylene Blue Have to Be Always Present in the Stocking of Emergency Antidotes
Current Drug Targets Causal Mechanisms Underlying Periventricular Leukomalacia and Cerebral Palsy
Current Pediatric Reviews Potential Role of microRNAs in Cardiovascular Disease: Are They up to Their Hype?
Current Cardiology Reviews Editorial [Hot Topic: Sepsis (Guest Editor: David E. Joyce)]
Current Drug Targets